Login to Your Account

StressGen, Roche Deal Worth Up To $204M For HPV Drug

By Randall Osborne

Tuesday, June 25, 2002
StressGen Biotechnologies Corp. found a partner for its lead drug to treat the human papilloma virus, nailing down a deal worth up to $204 million in milestone payments with F. Hoffmann-La Roche Ltd., which includes a $5 million equity investment and an undisclosed up-front payment on signing the deal. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription